4.8 Article

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Journal

SCIENCE
Volume 368, Issue 6491, Pages 630-+

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abb7269

Keywords

-

Funding

  1. National Institutes of Health [K99 AI139445]
  2. Calmette and Yersin scholarship from the Pasteur International Network Association
  3. Bill and Melinda Gates Foundation [OPP1170236]
  4. Guangzhou Medical University High-level University Innovation Team Training Program ((Guangzhou Medical University released [2017]) [159]
  5. National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme [N_HKU737/18]
  6. National Cancer Institute [ACB-12002]
  7. National Institute of General Medical Sciences [AGM-12006]
  8. DOE Office of Science [DE-AC02-06CH11357]

Ask authors/readers for more resources

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has now become a pandemic, but there is currently very little understanding of the antigenicity of the virus. We therefore determined the crystal structure of CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient, in complex with the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein at 3.1-angstrom resolution. CR3022 targets a highly conserved epitope, distal from the receptor binding site, that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Structural modeling further demonstrates that the binding epitope can only be accessed by CR3022 when at least two RBDs on the trimeric S protein are in the up conformation and slightly rotated. These results provide molecular insights into antibody recognition of SARS-CoV-2.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available